Global Monoclonal Antibody Therapeutics Market / mABs Therapeutics Market Size, Share, and Trends Analysis Report - Industry Overview and Forecast to 2032
Pharmaceutical | Upcoming Report | May 2025 | Global | 350 Pages | No of Tables: 220 | No of Figures: 60
Circumvent the Tariff challenges with an agile supply chain Consulting
Supply Chain Ecosystem Analysis now part of DBMR Reports
Global Monoclonal Antibody Therapeutics Market
Market Size in USD Billion
CAGR :
%
USD
263.22 Billion
USD
719.81 Billion
2024
2032
Forecast Period
2025 –2032
Market Size(Base Year)
USD
263.22 Billion
Market Size (Forecast Year)
USD
719.81 Billion
CAGR
%
Major Markets Players
F. Hoffmann-La Roche Ltd
Johnson & Johnson Services Inc.
Merck & Co. Inc.
Amgen Inc.
Sanofi
Global Monoclonal Antibody Therapeutics Market / mABs Therapeutics Market Segmentation, By Application (Cancer, Autoimmune Diseases, Infection, Hematological Diseases and Others), By Source (Human, Humanized, Chimeric and Others), End User (Hospitals, Private Clinics and Research Institute) - Industry Trends and Forecast to 2032
The global monoclonal antibody therapeutics market / mABs therapeutics market size was valued at USD 263.22 billion in 2024 and is expected to reach USD 719.81 billion by 2032,at a CAGR of 13.40% during the forecast period
This growth is driven by factors such as rising prevalence of chronic, emergence of biosimilars and advancement in biotechnology
Monoclonal antibody (mAb) therapeutics are pivotal in treating various diseases, including cancer, autoimmune disorders, and infectious diseases. Their specificity and efficacy have led to widespread adoption in modern medicine
The demand for mAb therapies is significantly driven by the increasing prevalence of chronic diseases and advancements in biotechnology and genetic engineering. Techniques such as recombinant DNA technology and hybridoma methods have enhanced the development and production of monoclonal antibodies
North America is expected to dominate the monoclonal antibody therapeutics market with market share of 45.7% due to advanced healthcare infrastructure, substantial healthcare expenditure, and strong regulatory support
Asia-Pacific is expected to be the fastest growing region in the monoclonal antibody therapeutics market, with a market share of 30.6% during the forecast period. This growth is driven by rapid expansion in healthcare infrastructure, increasing awareness about chronic diseases, and rising demand for advanced therapeutic
The cancer segment is expected to dominate the market with a market share of 50.5% in 2025, driven by the high prevalence of various cancers and the effectiveness of mAb therapies in targeting specific cancer cells such as those in breast cancer, lung cancer, and lymphoma
Expansion of mAb Applications in Emerging Diseases
Growth of Biosimilars in Cost-Sensitive Markets
Value Added Data Infosets
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include import export analysis, production capacity overview, production consumption analysis, price trend analysis, climate change scenario, supply chain analysis, value chain analysis, raw material/consumables overview, vendor selection criteria, PESTLE Analysis, Porter Analysis, and regulatory framework.
“Increasing Integration of Advanced Antibody Engineering and Precision Targeting Technologies”
One prominent trend in the evolution of monoclonal antibody therapeutics is the increasing integration of advanced antibody engineering and precision targeting technologies
These innovations enhance therapeutic efficacy by enabling antibodies to bind selectively to disease-specific antigens, reducing off-target effects and improving patient safety profiles
For instance, next-generation mABs—such as bispecific antibodies and antibody-drug conjugates (ADCs)—are revolutionizing treatment by combining targeting precision with potent cytotoxic activity, particularly in oncology and hematological malignancies
These advancements are transforming the landscape of disease treatment, expanding the range of treatable conditions, improving patient outcomes, and driving the demand for personalized, next-generation biologics in the global mAb therapeutics market
“Rising Prevalence of Chronic and Autoimmune Diseases Fueling Demand”
The increasing global burden of chronic conditions such as cancer, rheumatoid arthritis, multiple sclerosis, and Crohn’s disease is significantly driving the demand for monoclonal antibody therapeutics
These diseases often require long-term treatment strategies, and monoclonal antibodies offer targeted, effective, and often better-tolerated alternatives to conventional therapies
As awareness increases and more patients gain access to advanced biologics, the demand for mABs continues to rise across both developed and developing regions
For instance,
In October 2023, according to a report by the World Health Organization (WHO), over 41 million people die each year from noncommunicable diseases, representing 74% of all global deaths, with cancer and autoimmune disorders being major contributors. The WHO emphasized the need for innovative therapies such as monoclonal antibodies to manage these rising health burdens
As a result, pharmaceutical companies are investing heavily in research and development of next-generation monoclonal antibodies to meet the rising global need and address more disease targets
Opportunity
“Advancements in Antibody Engineering and Personalized Medicine”
Innovations in antibody engineering, such as bispecific antibodies, antibody-drug conjugates (ADCs), and Fc-engineered mABs, are expanding the capabilities of mAb therapeutics across diverse therapeutic areas
These advanced formats allow for enhanced specificity, improved immune system activation, and better delivery of cytotoxic agents directly to diseased cells, minimizing harm to healthy tissue
The rise of personalized medicine and companion diagnostics further strengthens the potential of monoclonal antibodies by aligning treatments with individual patient profiles, improving outcomes, and reducing trial-and-error in treatment protocols
For instance,
In January 2024, a study published in Nature Reviews Drug Discovery highlighted that over 180 monoclonal antibodies are currently in clinical trials, many of which incorporate targeted delivery and biomarker-based patient selection. These strategies represent a shift toward precision therapies that offer higher efficacy and lower toxicity
The synergy of antibody engineering with genomics and data-driven drug design is expected to revolutionize treatment paradigms and unlock new growth avenues in the global mAb market
Restraint/Challenge
“High Manufacturing and Therapy Costs Limiting Accessibility”
The complex manufacturing processes of monoclonal antibodies, including cell culture, purification, and quality control, contribute to very high production costs, which are often passed on to patients and healthcare systems
These therapies can cost tens of thousands of dollars per year per patient, posing significant challenges for affordability and inclusion in public or private reimbursement schemes—especially in low- and middle-income countries
Moreover, the need for cold-chain logistics, sterile facilities, and specialized healthcare professionals for administration further adds to the cost burden
For instance,
According to a March 2024 report from the Journal of the American Medical Association (JAMA), the average annual treatment cost for monoclonal antibody therapies in the U.S. exceeds USD 100,000 per patient, making them among the most expensive drug classes. The report emphasized that such high prices may delay or prevent access to treatment for patients without comprehensive insurance coverage
These barriers not only limit patient access to life-saving therapies but also slow market penetration in resource-constrained settings, posing a key challenge to market growth and equitable healthcare delivery
The market is segmented on the basis of application, source and end user.
Segmentation
Sub-Segmentation
By Application
Cancer
Autoimmune Diseases
Infection
Hematological Diseases
Others
By Source
Human
Humanized
Chimeric
Others
By End User
Hospitals
Private Clinics and
Research Institute
In 2025, the cancer is projected to dominate the market with a largest share in application segment
The cancer segment is expected to dominate the monoclonal antibody therapeutics market / mABs therapeutics market with the largest share of 50.5% in 2025 due to its high prevalence and the effectiveness of mAb therapies in targeting specific cancer cells, such as in breast cancer, lung cancer, and lymphoma. As the leading therapeutic approach for cancer treatment, advancements in monoclonal antibody engineering and targeted therapies continue to improve patient outcomes, driving market growth. Increased cancer incidences globally further contribute to its market dominance.
The human segmentis expected to account for the largest share during the forecast period in source market
In 2025, the human segment is expected to dominate the monoclonal antibody therapeutics market with the largest market share of 44.7% due to their lower immunogenicity and better patient tolerance, making them the preferred choice in therapeutic development. Advancements in genetic engineering have enabled the production of highly specific and low-immunogenic antibodies, improving therapeutic outcomes and driving market growth. The growing demand for more effective and targeted treatments for chronic diseases further contributes to its market dominance.
“North America Holds the Largest Share in the Monoclonal Antibody Therapeutics Market / mABs Therapeutics Market”
North America dominates the monoclonal antibody therapeutics market, accounting for approximately 45.7% of the total market share. This dominance is driven by advanced healthcare infrastructure, high adoption of cutting-edge medical technologies, and the strong presence of key market players in the region
U.S. holds a significant share of this, with approximately 73.8% of North America's market share, due to the increasing demand for high-precision therapeutics, the rising prevalence of chronic diseases such as cancer, rheumatoid arthritis, and autoimmune disorders, and continuous advancements in biotechnology and genetic engineering
The availability of well-established reimbursement policies and growing investments in research & development by leading pharmaceutical and biotech companies further strengthen the market
In addition, the growing adoption of biosimilars and personalized medicine, along with regulatory support, is fueling market expansion across North America
“Asia-Pacific is Projected to Register the Highest CAGR in the Monoclonal Antibody Therapeutics Market / mABs Therapeutics Market”
Asia-Pacific is expected to witness the highest growth rate in the monoclonal antibody therapeutics market, with a projected CAGR of 12.4% during the forecast period. This growth is driven by rapid expansion in healthcare infrastructure, increasing awareness about chronic diseases, and rising demand for advanced therapeutics
The region is expected to hold approximately 30.6% of the global market share by 2025, with China, India, and Japan emerging as key markets
Japan, with its advanced medical technology and increasing healthcare spending, remains a crucial market for monoclonal antibodies, accounting for 40% of the Asia-Pacific market share. Japan is at the forefront of adopting innovative biologics and targeted therapies to enhance patient outcomes
India is projected to register the highest CAGR in the market, with a share of approximately 18.9% in the Asia-Pacific market, driven by expanding healthcare infrastructure, rising awareness about advanced treatments, and a growing patient base seeking access to monoclonal antibody therapies for various chronic conditions
The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.
The Major Market Leaders Operating in the Market Are:
Latest Developments in Global Monoclonal Antibody Therapeutics Market / mABs Therapeutics Market
In January 2025, Roche announced the initiation of Phase III clinical trials for its novel monoclonal antibody RGX-202, targeting HER2-positive gastric cancer. This highlights Roche’s continued leadership in oncology biologics by expanding its pipeline to address unmet needs in gastric cancer treatment
In February 2025, AbbVie received FDA approval for Skyrizi (risankizumab) for the treatment of moderate to severe Crohn’s disease. Skyrizi, a humanized monoclonal antibody, previously approved for psoriasis, represents AbbVie’s growing dominance in the autoimmune therapeutic segment
In March 2025, the European Medicines Agency (EMA) approved Darzalex Faspro (daratumumab and hyaluronidase-fihj) by Johnson & Johnson for newly diagnosed multiple myeloma. This subcutaneous version offers increased convenience and reduced infusion time for patients
In April 2025, Merck announced positive Phase III results from the KEYNOTE-522 trial for Keytruda (pembrolizumab) in early-stage triple-negative breast cancer, demonstrating improved response rates when combined with chemotherapy
In May 2025, the European Commission approved Tezepelumab, developed by Amgen, for severe asthma. This monoclonal antibody targets thymic stromal lymphopoietin (TSLP), offering a new treatment option for patients unresponsive to standard therapies
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
Interactive Data Analysis Dashboard
Company Analysis Dashboard for high growth potential opportunities
Research Analyst Access for customization & queries
Competitor Analysis with Interactive dashboard
Latest News, Updates & Trend analysis
Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Research Methodology
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Customization Available
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
Claudio Rondena
Group Business Development & Strategic Marketing Director, C.O.C Farmaceutici SRL
"This morning we were involved in the first part, the data presentation of MKT analysis, selected abstract from your work. The board team was really impressed and very appreciated, as well."
David Manning - Thermo Fisher Scientific
Director, Global Strategic Accounts,
Dear Ricky, I want to thank you for the excellent market analysis (LIMS INSTALLED BASE DATA) that you and your team delivered, especially end of year on short notice.
Sachin and Shraddha captured the requirements, determined their path forward and executed quickly.
You, Sachin and Shraddha have been a pleasure to work with – very responsive, professional and thorough.
Your work is much appreciated.
Manager - Market Analytics,
Uriah D. Avila - Zeus Polymer Solutions
Thank you for all the assistance and the level of detail in the market report. We are very pleased with the results and the customization. We would like to continue to do business.
Business Development Manager,
(Pharmaceuticals Partner for Nasal Sprays) | Renaissance Lakewood LLC
DBMR was attentive and engaged while discussing the Global Nasal Spray Market. They understood what we were looking for and was able to provide some examples from the report as requested. DBMR Service team has been responsive as needed. Depending on what my colleagues were looking for, I will recommend your services and would be happy to stay connected in case we can utilize your research in the future.
Business Intelligence and Analytics,
Ipsen Biopharm Limited
We are impressed by the CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT report - so a BIG thanks to you colleagues.
Competition Analyst,
Basler Web
I just wanted to share a quick note and let you know that you guys did a really good job. I’m glad I decided to work with you. I shall continue being associated with your company as long as we have market intelligence needs.
Marketing Director,
Buhler Group
It was indeed a good experience, would definitely recommend and come back for future prospects.
COO,
A global leader providing Drug Delivery Services
DBMR did an outstanding job on the Global Drug Delivery project, We were extremely impressed by the simple but comprehensive presentation of the study and the quality of work done. This report really helped us to access untapped opportunities across the globe.
Marketing Director,
Philips Healthcare
The study was customized to our targets and needs with well-defined milestones. We were impressed by the in-depth customization and inclusion of not only major but also minor players across the globe. The DBMR Market position grid helped us to analyze the market in different dimension which was very helpful for the team to get into the minute details.
Product manager,
Fujifilms
Thankful to the team for the amazing coordination, and helping me at the last moment with my presentation. It was indeed a comprehensive report that gave us revenue impacting solution enabling us to plan the right move.
Investor relations,
GE Healthcare
Thank you for the report, and addressing our needs in such short time. DBMR has outdone themselves in this project with such short timeframe.
Market Analyst,
Medincell
We found the results of this study compelling and will help our organization validate a market we are considering to enter. Thank you for a job well done.
Andrew - Senior Global Marketing Manager,
Medtronic (US)
I want to thank you for your help with this report – It’s been very helpful in our business planning and it well organized.
Amarildo - Manager, Global Strategic Alignment
MasterCard
We believe the work done by Data Bridge Team for our requirements in the North America Loyalty Management Market was fantastic and would love to continue working with your team moving forward.
Tor Hammer
Green Nexus LLc
Thank you for your quick response to this unfortunate circumstance. Please extend my thanks to your reach team. I will be contacting you in the future with further projects
I acknowledge the difficulty given by the very short warning for this report, and I think that its quality and your delivering time have been very satisfying.
Obviously, as a provider Data Bridge Market Research will be considered as a plus for future needs of Nippon Gases.
Yuki Kopyl (Asian Business Development Department)
UENO FOOD TECHNO INDUSTRY, LTD. (JAPAN)
Xylose report was very useful for our team. Thank you very much & hope to work with you again in the future